Jasper Closes Kira Deal, Extends Cash Runway - Jasper Therapeutics (NASDAQ:JSPR)
Jasper Therapeutics (NASDAQ:JSPR) closed a deal with Kira and completed a private placement of non-voting convertible preferred stock raising about $132 million gross. The company expects cash to fund operations through 2H 2028. Jasper out-licensed Kira’s KP-301 and KP-402 to Mirador for $12 million upfront plus milestones. JSPR shares rose 20.67% to $0.9250.
How this was made
The 30-second read
Why it matters
The disclosed capital raise and runway through 2H 2028 reduce immediate funding risk, while the planned Phase 2 and FDA meetings create a clear catalyst calendar into 2026-2027.
Market read
Traders get a concrete liquidity update (about $132M gross proceeds, runway through 2H 2028) plus a multi-asset clinical/regulatory timeline that can drive positioning.
What to watch
The article does not quantify net proceeds, dilution terms, or the merger economics beyond the Kira asset out-licensing, which can materially affect valuation and near-term trading.
Background
Jasper Therapeutics is combining with Kira and closing a non-voting convertible preferred private placement to fund an expanded immunology pipeline.
Ticker impact
Jasper closed a private placement raising about $132M and expects cash to fund operations through 2H 2028, alongside a Kira deal close.
Near-term support from runway extension and deal completion, with volatility tied to clinical/regulatory milestones.
The article discloses a fresh $132M gross raise and runway guidance through 2H 2028, plus specific planned trial and FDA touchpoints for multiple assets.
Market effects
Biotech financing conditions and immunology pipeline competition remain active, with investors focusing on runway and near-term Phase 2 readouts.
Primarily US small/mid-cap biotech sentiment via Nasdaq-listed JSPR.
Limited direct global spillover; could marginally affect sentiment around complement and immunology drug development.
Counterpoint
The $132M raise and merger-related changes can be dilutive and may not de-risk clinical outcomes, so the stock move could fade if investors focus on execution rather than runway.
Key entities
- companyJasper Therapeutics
Nasdaq-listed biotech that closed the Kira deal and raised about $132M to fund operations through 2H 2028.
- companyKira
Out-licensed KP-301 and KP-402 assets to Mirador Therapeutics for $12M upfront plus milestones, as part of the combined transaction.
- companyMirador Therapeutics
Receives KP-301 and KP-402 via out-licensing in exchange for $12M upfront and potential milestones.
- analyst_firmWilliam Blair
Suspended its rating on Jasper following the merger due to meaningful changes and updated estimates.
